150 related articles for article (PubMed ID: 1598949)
21. [High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases].
Klein M; Kaminsky P; Duc M
Therapie; 1993; 48(2):97-103. PubMed ID: 8351694
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immune globulin in neuromuscular disorders.
Gupta S
West J Med; 1997 Nov; 167(5):349-50. PubMed ID: 9392991
[No Abstract] [Full Text] [Related]
23. ASHP national survey of pharmaceutical services in federal hospitals--1993.
Crawford SY; Santell JP
Am J Hosp Pharm; 1994 Oct; 51(19):2377-93. PubMed ID: 7847403
[TBL] [Abstract][Full Text] [Related]
24. The formulary system revisited.
Lantos RL
Hosp Formul; 1979 Jun; 14(6):664, 662. PubMed ID: 10297481
[No Abstract] [Full Text] [Related]
25. [Current therapeutic use of gamma globulin preparations].
Litzman J
Cas Lek Cesk; 1991 Nov; 130(18-19):556-60. PubMed ID: 1764720
[TBL] [Abstract][Full Text] [Related]
26. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions.
Robinson P; Anderson D; Brouwers M; Feasby TE; Hume H;
Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S3-8. PubMed ID: 17397767
[TBL] [Abstract][Full Text] [Related]
27. Immune globulin intravenous products--notice to hospitals.
Hogan V
CMAJ; 1999 Apr; 160(7):1051-2, 1055-6. PubMed ID: 10207352
[No Abstract] [Full Text] [Related]
28. Comments on ASHP guidelines for preventing medication errors.
Myers CE
Am J Hosp Pharm; 1993 May; 50(5):914. PubMed ID: 8506870
[No Abstract] [Full Text] [Related]
29. ASHP statement on the pharmacy and therapeutics committee.
Am J Hosp Pharm; 1986 Nov; 43(11):2841-2. PubMed ID: 3799625
[No Abstract] [Full Text] [Related]
30. ASHP statement on the pharmacy and therapeutics committee.
Am J Hosp Pharm; 1978 Jul; 35(7):813-4. PubMed ID: 665701
[No Abstract] [Full Text] [Related]
31. Comments on ASHP guidelines for preventing medication errors.
Cohen MR; Davis NM
Am J Hosp Pharm; 1993 May; 50(5):913. PubMed ID: 8506868
[No Abstract] [Full Text] [Related]
32. ASHP guidelines for institutional use of controlled substances.
Am J Hosp Pharm; 1974 Jun; 31(6):582-8. PubMed ID: 4407475
[No Abstract] [Full Text] [Related]
33. ASHP guidelines on preventing medication errors in hospitals.
Am J Hosp Pharm; 1993 Feb; 50(2):305-14. PubMed ID: 8480790
[No Abstract] [Full Text] [Related]
34. ASHP guidelines on hospital drug distribution and control (with references).
Am J Hosp Pharm; 1980 Aug; 37(8):1097-103. PubMed ID: 7405941
[No Abstract] [Full Text] [Related]
35. Intravenous immune globulin for multiple sclerosis.
Tecnologica MAP Suppl; 1998 Aug; ():3-5. PubMed ID: 10342975
[No Abstract] [Full Text] [Related]
36. ASHP guidelines for implementing and obtaining compensation for clinical services by pharmacists.
Am J Hosp Pharm; 1985 Jul; 42(7):1581-2. PubMed ID: 4025362
[No Abstract] [Full Text] [Related]
37. ASHP guidelines on the pharmacist's role in home care. American Society of Hospital Pharmacists.
Am J Hosp Pharm; 1993 Sep; 50(9):1940-4. PubMed ID: 8135245
[No Abstract] [Full Text] [Related]
38. Intravenous immune globulin for recurrent fetal loss.
Tecnologica; 1995 Nov; ():7-8. PubMed ID: 10168306
[No Abstract] [Full Text] [Related]
39. Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.
CMAJ; 1992 Jan; 146(2):121-4. PubMed ID: 1735037
[No Abstract] [Full Text] [Related]
40. Differences between IGIV products: impact on clinical outcome.
Gelfand EW
Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
